Videos

Targeted Oncology spoke with Howard D. Edington, MD, about the advancements in engineering oncolytic viruses to be able to target specific cancers and various combination therapies with the novel treatment.

In this concluding segment, Dr. Shore will share clinical pearls and practical insights regarding the optimal management of patients with metastatic hormone-sensitive prostate cancer.

Dr. Shore will highlight the importance of a multidisciplinary approach in the management of patients with mHSPC and the roles of various healthcare professionals in providing comprehensive care.

Dr. Shore will discuss the factors that guide treatment choices for mHSPC patients with a high disease burden and comorbidities.

In this segment, Dr. Shore will review the findings of several pivotal Phase 3 trials evaluating the efficacy of various treatments in metastatic hormone-sensitive prostate cancer patients, including the MAGNITUDE, PROpel, and TALAPRO-2 trials, among others.

Dr. Shore will provide an overview of the Phase 3 ARASENS trial, which evaluated the efficacy of the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel in hormone-sensitive prostate cancer patients. He will discuss the potential benefits of this combination in patients with high tumor burden mHSPC.

Dr. Shore will explore the evidence supporting treatment intensification through combining or sequencing therapies in metastatic prostate cancer. He will discuss the potential benefits and downsides of this approach, as well as which patients may benefit from an intensified treatment strategy.

Key findings from COMFORT I and COMFORT II studies are examined.

Expert panelists highlight the COMFORT I and COMFORT II studies.

In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.

Dr. Shore will provide his initial impressions of the patient case, including an assessment of the patient's risk level and how this influences clinical decision-making.

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.

Deric Park, MD, discusses a phase 1/2 study of IGV-001, a novel treatment for glioblastoma.

Deric Park, MD, discusses what challenges remain in treating glioblastoma, as well as new avenues for research in this difficult disease.

The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.

Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.

Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.

In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical trials aimed at replacing steroids as the first-line treatment approach.

In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.

Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.

Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this patient population.

Medical experts discuss a patient case highlighting a 68-year old woman who is uninterested in transplantation and treatment with ruxolitinib has been initiated.

This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.

Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations.

Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association Annual Meeting.

Arlene O. Siefker-Radtke, MD, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib, an FGFR1-4 inhibitor.